ClinConnect ClinConnect Logo
Search / Trial NCT06468384

Sympatholytic Effects of High Thoracic Erector Spinae Plane Block: Changes in Optic Nerve Sheath Diameter

Launched by PAMUKKALE UNIVERSITY · Jun 15, 2024

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called the thoracic erector spinae plane (ESP) block, which may help relieve pain in people with complex regional pain syndrome—a condition that causes chronic pain in certain areas of the body. The trial is particularly interested in how this treatment might affect the optic nerve, which could give clues about pressure changes in the brain. By looking at these changes, researchers hope to learn more about how safe and effective the ESP block is.

To participate in this study, you need to be an adult aged 18 to 65 who experiences neck, shoulder, or arm pain, specifically due to complex regional pain syndrome. The study will include 15 participants, and you will receive the ESP block treatment during the trial. However, there are some conditions that might prevent you from joining, such as certain heart problems, kidney or liver failure, or if you are pregnant. If you are eligible, you can expect to undergo the treatment and have your optic nerve monitored closely to see how your body responds.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Adults with neck, shoulder, and arm pain
  • Those with complex regional pain syndrome
  • The study will include 15 adult patients who are planned to receive T2-ESP block treatment.
  • Age between 18-65 years
  • Both genders
  • ASA physical status I-II
  • Exclusion Criteria:
  • Those who refuse procedures and tests
  • Individuals with conditions that can increase intracranial pressure
  • Those with severe heart failure
  • Individuals with second or third-degree atrioventricular block
  • Those with a history of unstable angina
  • Individuals with COPD or chronic asthma
  • Those who have experienced a myocardial infarction (MI) within the last 6 weeks
  • Individuals with a heart rate below 50 beats per minute
  • Those with systolic blood pressure below 90 mmHg
  • Individuals with liver failure
  • Those with kidney failure
  • Individuals for whom a supraclavicular block is anatomically impossible
  • Those with neurological or psychological conditions that complicate test evaluation
  • Individuals allergic to any of the study medications
  • Pregnant individuals

About Pamukkale University

Pamukkale University is a renowned academic institution located in Denizli, Turkey, dedicated to advancing medical research and education. As a clinical trial sponsor, the university leverages its extensive resources and expertise to facilitate innovative studies aimed at improving patient outcomes and contributing to the broader scientific community. With a commitment to ethical standards and regulatory compliance, Pamukkale University fosters collaboration among researchers, healthcare professionals, and industry partners, ensuring the rigorous execution of clinical trials that address critical health challenges. Through its research initiatives, the university aims to enhance the understanding of various medical conditions and support the development of effective therapies.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported